Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Big Is The Endocrine Peptide Test Market Today And What Is Its Future Size?

Recently, there has been robust growth in the market size of endocrine peptide test. It is projected to expand from $9.11 billion in 2024 to a higher value of $9.95 billion in 2025, with a compound annual growth rate (CAGR) of 9.3%. The noteworthy expansion in the previous years can be traced back to factors like increased government expenditure, a surge in diabetes cases, diminishing immunity levels worldwide, the high threat of chronic diseases, and increasing government initiatives.

The market size for endocrine peptide tests is projected to register significant expansion in the coming years. It is anticipated to reach $13.9 billion in 2029, with a compound annual growth rate (CAGR) of 8.7%. Factors contributing to this expansion in the forecast period include the rising demand for endocrine peptide tests, a surge in research and development efforts, an increase in lifestyle-related diseases, a growing elderly population, and a high prevalence of diabetes. The forecast period is also expected to see key trends such as advancements in endocrine testing methods, improvements in product technologies, an emphasis on research and development to create innovative testing solutions, an increasing number of product approvals, and a shift towards preventive healthcare.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16675&type=smp

Which Demand Drivers Are Strengthening The Endocrine Peptide Test Market?

The escalating occurrence of diabetes is anticipated to boost the expansion of the endocrine peptide test market in the future. Diabetes constitutes a collection of diseases characterized by elevated blood sugar (glucose) levels. The frequent incidence of diabetes is escalating due to elements such as unhealthy eating patterns, inactive lifestyles, genetic susceptibility, and an aging populace. The endocrine peptide test, which encompasses hemoglobin A1c, fasting plasma glucose, and C-peptide tests, plays a critical role in diabetes in terms of identifying the disorders, overseeing glucose levels, and gauging insulin formation and responsiveness. For instance, in June 2024, as per data from the National Health Service (NHS), a UK-based government entity, there was a substantial increase in the number of people under 40 diagnosed with diabetes, surging from 173,166 in 2022 to 216,440 in 2023. This rapid growth highlights an alarming trend of elevated diabetes occurrence in younger generations. Hence, the mounting prevalence of diabetes is fueling the growth of the endocrine peptide test market.

Which Segment Accounts For The Largest Share In The Endocrine Peptide Test Market?

The endocrine peptide testmarket covered in this report is segmented –

1) By Test-Type: Dehydroepiandrosterone Sulphate; Progesterone; Luteinizing Hormone; Thyroid Prolactin; Oestradiol; Human Chorionic Gonadotropin; Thyroid-Stimulating Hormone; Other Test-Types

2) By Technology: Mass Spectroscopy; Immunoassay; Chromatography; Nucleic Acid Based; Other Technologies

3) By End-User: Clinics; Healthcare Centers; Hospitals; Commercial Laboratories

Subsegments:

1) By Dehydroepiandrosterone Sulphate (DHEA-S): Immunoassay Tests; Enzyme-Linked Immunosorbent Assay (ELISA); Radioimmunoassay (RIA)

2) By Progesterone: Immunoassay Tests; Chemiluminescence Assays; ELISA Tests

3) By Luteinizing Hormone (LH): Immunoassay Tests; Enzyme Immunoassay (EIA); Radioimmunoassay (RIA)

4) By Thyroid Prolactin: Immunoassay Tests; Chemiluminescence Assays; Radioimmunoassay (RIA)

5) By Oestradiol: Immunoassay Tests; Enzyme-Linked Immunosorbent Assay (ELISA); Radioimmunoassay (RIA)

6) By Human Chorionic Gonadotropin (hCG): Immunoassay Tests; Chemiluminescence Assays; Enzyme Immunoassay (EIA)

7) By Thyroid-Stimulating Hormone (TSH): Immunoassay Tests; Radioimmunoassay (RIA); Enzyme-Linked Immunosorbent Assay (ELISA)

8) Other Test-Types: Cortisol; Insulin; Growth Hormone (GH); Parathyroid Hormone (PTH)

Which Long-Term Trends Will Play A Crucial Role In The Endocrine Peptide Test Market?

Key players in the endocrine peptide test market are advancing immunoassay test systems aiming to enhance the precision, sensitivity, and swiftness for endocrine peptide tests. These systems employ antibodies to identify and quantify particular peptides in blood or urine samples, offering crucial data about hormone levels and endocrine functioning to healthcare practitioners. For example, in July 2023, Siemens Healthineers, a healthcare services firm based in Germany, introduced the Atellica CI Analyzer, a compact system devised for immunoassay and clinical chemistry tests, inclusive of endocrine peptide assays. The Atellica CI Analyzer also offers a reproductive endocrinology menu that comprises anti-Mullerian hormone (AMH) for assessing ovarian reserve and sFlt-1 and PlGF (placental growth factor) for assisting in the prognosis of preeclampsia. Engineered to provide consistent, high-quality results promptly, the Atellica CI Analyzer holds a capacity of up to 1000 tests per hour. It enhances workflow efficiency and adaptability to support laboratories in their changing testing requirements.

Which Companies Hold A Competitive Edge In The 943 Market?

Major companies operating in the endocrine peptide test market are Siemens AG, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Sciex, Bio-Techne Corporation, Invitae Corporation, ARUP Laboratories, Genova Diagnostics, Boston Heart Diagnostics Corporation, Immunodiagnostic Systems Ltd., Mayo Clinic Laboratories

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report

Which Region Is Forecasted To Lead The Endocrine Peptide Test Market In The Coming Years?

North America was the largest region in the endocrine peptide test market in 2024. The regions covered in the endocrine peptide test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=16675&type=smp

Browse Through More Reports Similar to the Global Endocrine Peptide Test Market 2025, By The Business Research Company

Biosimilar Therapeutic Peptide Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

Peptide Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Peptide Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model